The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial

Blood Coagul Fibrinolysis. 2011 Dec;22(8):760-2. doi: 10.1097/MBC.0b013e328349f1a8.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / complications
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / surgery
  • Aged
  • Canada
  • Colonic Neoplasms / blood
  • Colonic Neoplasms / complications
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / surgery
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / therapeutic use
  • Follow-Up Studies
  • Heparin, Low-Molecular-Weight / administration & dosage*
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Odds Ratio
  • Perioperative Period
  • Pilot Projects
  • Tinzaparin
  • Venous Thromboembolism / blood
  • Venous Thromboembolism / complications
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / surgery

Substances

  • Fibrinolytic Agents
  • Heparin, Low-Molecular-Weight
  • Tinzaparin